Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
Sana Biotechnology, Inc. (SANA)
Company Research
Source: GlobeNewswire
Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells, GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025Announced increased focus on type 1 diabetes and B-cell mediated autoimmune diseases ?Cash position of $199.0 million with expected cash runway into 2026 SEATTLE, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the third quarter 2024. “Early clinical data with our hypoimmune technology suggest HIP-modified cel
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- ATTENTION SANA SHAREHOLDERS: Investors who lost money on Sana Biotechnology, Inc. are urged to contact Levi & Korsinsky about an ongoing investigationAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANAAccesswire
- Shareholder Rights Advocates at Levi & Korsinsky Investigate Sana Biotechnology, Inc. (SANA) Regarding Possible Securities Fraud ViolationsAccesswire
- Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SANAAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANAPR Newswire
SANA
Earnings
- 11/8/24 - Miss
SANA
Sec Filings
- 11/21/24 - Form 3/A
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- SANA's page on the SEC website